LU91036I2 - Adefovir dipivoxil et ses dérivés pharmaceutiquement acceptables (hepsera) - Google Patents

Adefovir dipivoxil et ses dérivés pharmaceutiquement acceptables (hepsera)

Info

Publication number
LU91036I2
LU91036I2 LU91036C LU91036C LU91036I2 LU 91036 I2 LU91036 I2 LU 91036I2 LU 91036 C LU91036 C LU 91036C LU 91036 C LU91036 C LU 91036C LU 91036 I2 LU91036 I2 LU 91036I2
Authority
LU
Luxembourg
Prior art keywords
hepsera
pharmaceutically acceptable
acceptable derivatives
adefovir dipivoxil
agents
Prior art date
Application number
LU91036C
Other languages
English (en)
Original Assignee
Acad Of Science Czech Republic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24335088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91036(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acad Of Science Czech Republic filed Critical Acad Of Science Czech Republic
Publication of LU91036I2 publication Critical patent/LU91036I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
    • C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
LU91036C 1990-09-14 2003-08-13 Adefovir dipivoxil et ses dérivés pharmaceutiquement acceptables (hepsera) LU91036I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58390690A 1990-09-14 1990-09-14

Publications (1)

Publication Number Publication Date
LU91036I2 true LU91036I2 (fr) 2003-10-13

Family

ID=24335088

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91036C LU91036I2 (fr) 1990-09-14 2003-08-13 Adefovir dipivoxil et ses dérivés pharmaceutiquement acceptables (hepsera)

Country Status (12)

Country Link
US (2) US5663159A (fr)
EP (1) EP0481214B1 (fr)
JP (1) JP3164385B2 (fr)
AT (1) ATE167679T1 (fr)
BR (1) BR1100467A (fr)
CA (1) CA2051239C (fr)
DE (2) DE69129650T2 (fr)
DK (1) DK0481214T3 (fr)
ES (1) ES2118069T3 (fr)
HK (1) HK1010053A1 (fr)
LU (1) LU91036I2 (fr)
NL (1) NL300131I2 (fr)

Families Citing this family (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06510020A (ja) * 1991-03-29 1994-11-10 ユニバーシティ・オブ・フロリダ 混成リン酸エステル誘導体を経た標的への薬剤供給
DE4142570A1 (de) * 1991-12-21 1993-06-24 Basf Ag Glykolaldehyd- und milchsaeurederivate, deren herstellung und verwendung
GB9205917D0 (en) * 1992-03-18 1992-04-29 Smithkline Beecham Plc Pharmaceuticals
US5849905A (en) * 1994-11-23 1998-12-15 Centre National De La Recherche Scientifique Biologically active phosphotriester-type nucleosides and methods for preparing same
FR2691463A1 (fr) * 1992-05-25 1993-11-26 Centre Nat Rech Scient Dérivés nucléotidiques, leur préparation et leur application en thérapeutique.
US6020482A (en) * 1992-05-25 2000-02-01 Gosselin; Gilles Phosphotriester type biologically active compounds
FR2692265B1 (fr) * 1992-05-25 1996-11-08 Centre Nat Rech Scient Composes biologiquement actifs de type phosphotriesters.
US5770725A (en) * 1992-05-25 1998-06-23 Gosselin; Gilles Phosphotriester type biologically active compounds
US6057305A (en) * 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
US5817647A (en) * 1993-04-01 1998-10-06 Merrell Pharmaceuticals Inc. Unsaturated acetylene phosphonate derivatives of purines
US5955591A (en) * 1993-05-12 1999-09-21 Imbach; Jean-Louis Phosphotriester oligonucleotides, amidites and method of preparation
CA2126601A1 (fr) * 1993-06-29 1994-12-30 Mitsubishi Chemical Corporation Derives d'ester phosphonate de nucleotide
JP4086314B2 (ja) * 1993-09-17 2008-05-14 ギリアード サイエンシーズ， インコーポレイテッド ヌクレオチドアナログ
US5656745A (en) * 1993-09-17 1997-08-12 Gilead Sciences, Inc. Nucleotide analogs
KR100386685B1 (ko) * 1993-09-17 2003-12-31 길리애드 사이언시즈, 인코포레이티드 뉴클레오타이드동족체류
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
US5627185A (en) * 1994-11-23 1997-05-06 Gosselin; Gilles Acyclovir derivatives as antiviral agents
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
US5717095A (en) * 1995-12-29 1998-02-10 Gilead Sciences, Inc. Nucleotide analogs
NZ325704A (en) * 1995-12-29 2000-02-28 Gilead Sciences Inc Nucleotide analogs
US6093816A (en) 1996-06-27 2000-07-25 Isis Pharmaceuticals, Inc. Cationic lipids
WO1998004569A1 (fr) * 1996-07-26 1998-02-05 Gilead Sciences, Inc. Analogues de nucleotides
US5922695A (en) * 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
AU713374B2 (en) * 1996-07-26 1999-12-02 Gilead Sciences, Inc. Nucleotide analogs
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
DE69809749T2 (de) * 1997-07-25 2003-09-11 Gilead Sciences, Inc. Nukleotid-analoge zusammensetzung
CN1763057B (zh) * 1997-07-25 2012-10-17 吉尔利德科学股份有限公司 核苷酸类似物组合物
US5935946A (en) * 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
ES2401070T3 (es) * 1998-03-06 2013-04-16 Metabasis Therapeutics, Inc. Nuevos profármacos para compuestos que contienen fósforo
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
KR100634342B1 (ko) * 1998-08-10 2006-10-16 이데닉스(케이만)리미티드 B형 간염의 치료용 β-L-2'-데옥시-뉴클레오시드
US6635278B1 (en) 1998-12-15 2003-10-21 Gilead Sciences, Inc. Pharmaceutical formulations
TWI230618B (en) * 1998-12-15 2005-04-11 Gilead Sciences Inc Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
MXPA01008937A (es) * 1999-03-05 2004-04-05 Metabasis Therapeutics Inc Nuevos profarmacos que contienen fosforo.
AU7361400A (en) * 1999-09-08 2001-04-10 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
EP1233770B1 (fr) * 1999-12-03 2008-02-13 The Regents of The University of California at San Diego Composes de phosphonate
IL150062A0 (en) * 1999-12-17 2002-12-01 Ariad Pharma Inc Proton pump inhibitors
AU2001245575A1 (en) * 2000-03-09 2001-09-17 Videoshare, Inc. Sharing a streaming video
HRP20160074B1 (hr) * 2000-07-21 2021-09-03 Gilead Sciences, Inc. Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava
MY141789A (en) * 2001-01-19 2010-06-30 Lg Chem Investment Ltd Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same.
CN1329404C (zh) 2001-06-29 2007-08-01 捷克科学院有机化学和生物化学研究所 具有抗病毒活性的6－2'－(膦酰基甲氧基)烷氧基嘧啶衍生物
AU2003299492B2 (en) 2002-05-13 2010-06-10 Metabasis Therapeutics, Inc. Cyclic prodrugs of PMEA one of its analogues
CA2485597C (fr) * 2002-05-13 2013-07-02 Metabasis Therapeutics, Inc. Procede destine a la preparation de promedicaments cycliques de la pmea et de la pmpa
EP1546164A4 (fr) * 2002-09-26 2006-06-07 Lg Life Sciences Ltd Trans-isomeres (+) de derives de nucleoside ( 1-phosphonomethoxy-2-alkylcyclopropyl)methyle, processus de preparation de stereo-isomeres de ceux-ci et utilisation d'agents antiviraux a base ceux-ci
WO2004035577A2 (fr) * 2002-10-16 2004-04-29 Gilead Sciences, Inc. Composes tricycliques pre-organises inhibiteurs d'integrase
CA2503730C (fr) 2002-10-31 2011-10-18 Metabasis Therapeutics, Inc. Promedicaments de cytarabine monophosphate
KR101101962B1 (ko) * 2002-11-12 2012-01-02 티안진 디실리 인베스트먼트 홀딩 그룹, 리미티드 새로운 결정 형태를 가진 아데포비어 디피복실의 제조 방법
WO2004064846A1 (fr) * 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions et methodes de polytherapie antivirale
JP5069463B2 (ja) 2003-04-25 2012-11-07 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス性ホスホネート類似物
SI1644389T1 (sl) 2003-06-16 2011-06-30 Acad Of Science Czech Republic Pirimidinske spojine s fosfonatnimi skupinami kot antivirusni nukleotidni analogi
US20050065171A1 (en) * 2003-06-25 2005-03-24 Shakespeare William C. Substituted purine derivatives
NZ544988A (en) * 2003-07-30 2009-11-27 Gilead Sciences Inc Nucleobase phosphonate analogs for antiviral treatment
AU2004274493A1 (en) * 2003-09-19 2005-03-31 Gilead Sciences, Inc. Aza-quinolinol phosphonate integrase inhibitor compounds
AU2004293013B2 (en) * 2003-11-19 2011-04-28 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
ES2350983T3 (es) * 2003-12-30 2011-01-28 Gilead Sciences, Inc. Fosfonatos, monofosfonamidatos, bisfosfonamidatos para el tratamiento de enfermedades víricas.
AU2005206511A1 (en) * 2004-01-12 2005-08-04 Gilead Sciences, Inc. Pyrimidyl phosphonate antiviral compounds and methods of use
US20080153783A1 (en) * 2004-01-12 2008-06-26 Gilead Sciences, Inc. Pyrimidyl Phosphonate Antiviral Compounds and Methods of Use
WO2005090370A1 (fr) 2004-02-05 2005-09-29 The Regents Of The University Of California Agents pharmacologiquement actifs contenant des phosphonates esterifies, et leurs procedes d'utilisation
EP1715873A1 (fr) * 2004-02-17 2006-11-02 LG Life Sciences Ltd. Derives de nucleoside phosphonate utiles dans le traitement d'infections vih
PT1742642E (pt) * 2004-04-14 2009-01-23 Gilead Sciences Inc Análogos de fosfonato de compostos inibidores da integrase do hiv
AU2005254940A1 (en) 2004-06-08 2005-12-29 Metabasis Therapeutics, Inc. Lewis acid mediated synthesis of cyclic esters
CN100338080C (zh) * 2004-06-16 2007-09-19 山东中科泰斗化学有限公司 9－[2－(膦羧基甲氧基)乙基]腺嘌呤双环醇酯及其制备方法
UA93354C2 (ru) 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
EP2316839B1 (fr) * 2004-07-16 2014-03-12 Gilead Sciences, Inc. Composés hétérocycliques antiviraux avec des groupes phosphonates
BRPI0512690A (pt) 2004-07-27 2007-11-27 Gilead Sciences Inc análogos de fosfonato de compostos inibidores de hiv
EP1865967A4 (fr) * 2005-04-08 2011-02-09 Chimerix Inc Composes, compositions et methodes de traitement d'infections virales et autres troubles medicaux
WO2006110655A2 (fr) 2005-04-08 2006-10-19 Chimerix, Inc. Composes, compositions et methodes de traitement des infections a poxvirus
TW200716632A (en) * 2005-05-16 2007-05-01 Gilead Sciences Inc Integrase inhibitor compounds
CA2606499C (fr) 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Composes thyromimetiques utilises pour traiter les maladies hepatiques graisseuses
RU2007148927A (ru) * 2005-05-26 2009-07-10 Метабэйзис Терапьютикс, Инк. (Us) Новые тиреомиметики, содержащие фосфиновую кислоту
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
CN100526315C (zh) 2005-06-16 2009-08-12 浙江医药股份有限公司新昌制药厂 N2-喹啉或异喹啉取代的嘌呤衍生物及其制备方法和其用途
TW200738742A (en) * 2005-07-14 2007-10-16 Gilead Sciences Inc Antiviral compounds
TWI389908B (zh) * 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
WO2007015824A2 (fr) 2005-07-25 2007-02-08 Intermune, Inc. Nouveaux inhibiteurs macrocycliques de la multiplication du virus de l’hépatite c
JP2009502964A (ja) * 2005-07-27 2009-01-29 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを阻害するための抗ウイルス性ホスホン酸結合体
NZ572367A (en) * 2006-05-16 2011-09-30 Gilead Sciences Inc Fused cyclic compounds as integrase inhibitors
WO2008005542A2 (fr) 2006-07-07 2008-01-10 Gilead Sciences, Inc., Composés antiviraux à base de phosphinate
ES2388969T3 (es) * 2006-07-07 2012-10-22 Gilead Sciences, Inc. Compuestos antivirales de fosfinato
JP5372751B2 (ja) * 2006-07-21 2013-12-18 ギリアード サイエンシーズ， インコーポレイテッド Ａｚａ−ペプチドプロテアーゼ阻害剤
US7723380B2 (en) * 2006-07-21 2010-05-25 Gilead Sciences, Inc. Antiviral protease inhibitors
FR2908133B1 (fr) * 2006-11-08 2012-12-14 Centre Nat Rech Scient Nouveaux analogues de nucleotides comme molecules precurseurs d'antiviraux
CN101190927B (zh) * 2006-11-30 2012-04-18 天津天士力集团有限公司 9-[2-(膦酰甲氧)乙基]腺嘌呤单特戊酰氧甲酯的制备方法
WO2008154817A1 (fr) 2007-06-18 2008-12-24 Zhang, Zhongneng Thiazolyl-dihydropyrimidines à substitution bromo-phényle
ITMI20071594A1 (it) * 2007-08-02 2009-02-03 Solmag Spa Forma cristallina monoidrata di adefovir dipivoxil
WO2009094191A2 (fr) * 2008-01-25 2009-07-30 Chimerix, Inc. Méthodes de traitement d’infections virales
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
US20110059921A1 (en) * 2008-03-27 2011-03-10 Ektar Therapeutics Oligomer-Nitrogenous Base Conjugates
NZ588670A (en) 2008-04-23 2012-08-31 Gilead Sciences Inc Carba-nucleoside analogs for antiviral treatment
TW201010692A (en) 2008-06-19 2010-03-16 Public Univ Corp Nagoya City Univ Pharmaceutical composition for treatment or prevention of hbv infection
AU2009268681B2 (en) 2008-07-08 2014-10-02 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
KR20100031045A (ko) * 2008-09-11 2010-03-19 씨제이제일제당 (주) 아데포비어 디피복실의 정제방법
KR20100032803A (ko) 2008-09-18 2010-03-26 씨제이제일제당 (주) 아데포비어디피복실의 개선된 제조방법
KR20110075019A (ko) * 2008-10-15 2011-07-05 인터뮨, 인크. 치료용 항바이러스성 펩티드
RU2485121C1 (ru) 2009-03-26 2013-06-20 Даевунг Фармасьютикал Ко., Лтд. Новые кристаллические формы адефовира дипивоксила и способы его получения
CN104211713B (zh) 2009-05-13 2017-04-12 吉利德制药有限责任公司 抗病毒化合物
US8614200B2 (en) 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
CA2773773C (fr) 2009-09-21 2019-04-23 Gilead Sciences, Inc. Procedes et intermediaires pour preparer des analogues de carba-nucleoside 1'-substitues
EA201200525A1 (ru) 2009-09-21 2012-09-28 Гайлид Сайэнсиз, Инк. 2'-фторзамещенные карба-нуклеозидные аналоги для противовирусного лечения
US20110082182A1 (en) * 2009-10-01 2011-04-07 Intermune, Inc. Therapeutic antiviral peptides
EP2343056A1 (fr) 2009-12-30 2011-07-13 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Production d'une dispersion solide stable d'adefovir dipivoxil sous forme amorphe.
US9006218B2 (en) 2010-02-12 2015-04-14 Chimerix Inc. Nucleoside phosphonate salts
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
CA2797601A1 (fr) 2010-04-26 2011-11-10 Chimerix, Inc. Methodes de traitement d'infections retrovirales et regimes posologiques associes
CN101812090B (zh) * 2010-05-10 2013-08-14 浙江车头制药股份有限公司 一种阿德福韦单酯的制备方法
JP2013526581A (ja) 2010-05-21 2013-06-24 ギリアード サイエンシーズ， インコーポレイテッド ヘテロ環式フラビウイルス科ウイルス阻害剤
PT2588450T (pt) 2010-07-02 2017-08-03 Gilead Sciences Inc Derivados do ácido naft-2-ilacético para tratamento da sida
PE20130525A1 (es) 2010-07-02 2013-05-05 Gilead Sciences Inc Derivados de acido 2 quinolinil acetico como compuestos antivirales frente a vih
EP2805960A1 (fr) 2010-07-19 2014-11-26 Gilead Sciences, Inc. Procédés pour la préparation de promédicaments de phosphoramidate pur diastéromérique
CN101891767B (zh) * 2010-07-21 2012-05-23 浙江贝得药业有限公司 一种阿德福韦酯的制备方法
CA2804840C (fr) 2010-07-22 2018-09-11 Gilead Sciences, Inc. Procedes et composes pour traiter des infections a virus paramyxoviridae
WO2012032541A1 (fr) 2010-09-06 2012-03-15 Matrix Laboratories Ltd Pseudopolymorphe d'adéfovir dipivoxil
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
AU2011306066B2 (en) 2010-09-20 2015-01-29 Gilead Sciences, Inc. 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
CN102093417B (zh) * 2010-11-15 2012-11-28 济南久创化学有限责任公司 一种可制备核苷膦酸类药物的化合物及其制备方法
PL2640719T3 (pl) 2010-11-17 2017-10-31 Gilead Pharmasset Llc Związki przeciwwirusowe
CA2818853A1 (fr) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides destines a la therapie contre le virus de l'hepatite c et le virus de la dengue
CA2819548C (fr) 2010-12-10 2019-04-09 Sigmapharm Laboratories, Llc Compositions tres stables d'analogues nucleotidiques actifs par voie orale ou de promedicaments sous forme d'analogues nucleotidiques actifs par voie orale
JP6043338B2 (ja) 2011-04-13 2016-12-14 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス治療用の１’−置換ピリミジンｎ−ヌクレオシド類似体
ES2615734T3 (es) 2011-04-21 2017-06-08 Gilead Sciences, Inc. Compuestos de benzotiazol y su uso farmacéutico
PT2729448E (pt) 2011-07-06 2015-12-02 Gilead Sciences Inc Compostos para o tratamento de vih
WO2013025788A1 (fr) 2011-08-16 2013-02-21 Gilead Sciences, Inc. Hémifumarate de ténofovir alafénamide
KR20210043734A (ko) 2011-11-16 2021-04-21 길리애드 파마셋 엘엘씨 항바이러스성 화합물로서의 축합된 이미다졸릴이미다졸
US9593137B2 (en) 2011-12-22 2017-03-14 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
WO2013103738A1 (fr) 2012-01-04 2013-07-11 Gilead Sciences, Inc. Dérivés d'acide naphtalène acétique contre l'infection par le vih
WO2013103724A1 (fr) 2012-01-04 2013-07-11 Gilead Sciences, Inc. Dérivés d'acide 2-(tert-butoxy)-2-(7-méthylquinoléin-6-yl)acétique pour traiter le sida
JP6242378B2 (ja) 2012-03-13 2017-12-06 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス処置のための２’−置換カルバヌクレオシド類似体
RU2014115227A (ru) 2012-04-20 2015-10-27 Джилид Сайэнс, Инк. Производные бензотиазол-6-ил уксусной кислоты и их примение для лечения вич-инфекции
WO2013167743A1 (fr) 2012-05-11 2013-11-14 Akron Molecules Gmbh Utilisation de composés pour le traitement de la douleur
US9079887B2 (en) 2012-05-16 2015-07-14 Gilead Sciences, Inc. Antiviral compounds
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
CN102977146B (zh) * 2012-11-20 2016-04-20 广东肇庆星湖生物科技股份有限公司 一种腺嘌呤衍生物的合成方法
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
JP6462659B2 (ja) 2013-03-15 2019-01-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 非環式ヌクレオシドホスホン酸ジエステル
CN110156838A (zh) * 2013-05-14 2019-08-23 北京美倍他药物研究有限公司 磷酸/膦酸衍生物及其医药用途
WO2015096697A1 (fr) * 2013-12-23 2015-07-02 四川海思科制药有限公司 Dérivé de phosphonate de nucléoside acyclique et procédé de préparation et son utilisation en science médicale
EP3623364A1 (fr) 2014-02-13 2020-03-18 Ligand Pharmaceuticals, Inc. Composés de promédicaments et leurs utilisations
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
WO2015197006A1 (fr) * 2014-06-25 2015-12-30 四川海思科制药有限公司 Composé thioester d'acide aminé substitué, et composition et application de celui-ci
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
RS63250B1 (sr) 2014-09-15 2022-06-30 Univ California Nukleotidni analozi
TWI740546B (zh) 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
GB201509431D0 (en) * 2015-06-01 2015-07-15 Equigerminal Sa Antiviral composition
EP3350191B9 (fr) 2015-09-15 2021-12-22 The Regents of the University of California Analogues nucléotidiques
CN116617233A (zh) 2015-09-16 2023-08-22 吉利德科学公司 治疗沙粒病毒科和冠状病毒科病毒感染的方法
CN105294762A (zh) * 2015-11-13 2016-02-03 中国药科大学 阿德福韦酯杂质的制备方法
CN106800573B (zh) * 2015-11-25 2020-03-10 四川海思科制药有限公司 一种核苷酸膦酸酯一水合物及其制备方法和在医药上的应用
KR102180740B1 (ko) 2016-08-19 2020-11-20 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물
WO2018039157A1 (fr) * 2016-08-25 2018-03-01 Merck Sharp & Dohme Corp. Promédicaments antiviraux du ténofovir
EP3519409B1 (fr) 2016-09-28 2024-09-18 Gilead Sciences, Inc. Dérivés d'acide benzothiazol-6-yl-acétique et leur utilisation pour le traitement d'une infection par le vih
EP3541395A4 (fr) 2016-11-21 2020-07-01 Viking Therapeutics, Inc. Méthodes de traitement de glycogénose
EP3372227A1 (fr) 2017-03-06 2018-09-12 MH10 Spolka z ograniczona odpowiedzialnoscia Formulation de comprimé d'adéfovir dipivoxil
EP4331677A3 (fr) 2017-03-14 2024-05-29 Gilead Sciences, Inc. Procédés de traitement d'infections à coronavirus félin
EP3618929B1 (fr) 2017-05-01 2022-12-07 Gilead Sciences, Inc. Forme cristalline de (s) 2 éthylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f][1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)méthoxy)(phénoxy) phosphoryl)amino)propanoate
JP7168660B2 (ja) 2017-06-05 2022-11-09 バイキング・セラピューティクス・インコーポレイテッド 線維症の処置のための組成物
CN111093627B (zh) 2017-07-11 2024-03-08 吉利德科学公司 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
EP3661937B1 (fr) 2017-08-01 2021-07-28 Gilead Sciences, Inc. Formes crystallines d'éthyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)méthyl)(phénoxy)phosphoryl)-l-alaninate (gs-9131) pour le traitement des infections virales
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TW202024061A (zh) 2017-08-17 2020-07-01 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
EP3737676B1 (fr) 2018-01-09 2024-03-06 Ligand Pharmaceuticals, Inc. Composés acétal et leurs utilisations thérapeutiques
PL3752495T3 (pl) 2018-02-15 2024-01-15 Gilead Sciences, Inc. Pochodne pirydynowe i ich zastosowanie do leczenia infekcji hiv
KR20230145536A (ko) 2018-02-16 2023-10-17 길리애드 사이언시즈, 인코포레이티드 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체
EP3768690A4 (fr) 2018-03-22 2021-11-24 Viking Therapeutics, Inc. Formes cristallines et procédés de production de formes cristallines d'un composé
JP2021530523A (ja) 2018-07-16 2021-11-11 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のためのカプシド阻害剤
WO2020117962A1 (fr) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions pour le traitement de la fibrose et de l'inflammation
US20240139325A1 (en) 2019-10-17 2024-05-02 Ai-Biopharma Anti-viral and hepatic-targeted drugs
US11807625B2 (en) 2019-11-26 2023-11-07 Gilead Sciences, Inc. Capsid inhibitors for the prevention of HIV
AU2021214911A1 (en) 2020-01-27 2022-07-21 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
TWI785528B (zh) 2020-03-12 2022-12-01 美商基利科學股份有限公司 1’-氰基核苷之製備方法
US11701372B2 (en) 2020-04-06 2023-07-18 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs
JP2023528810A (ja) 2020-05-29 2023-07-06 ギリアード サイエンシーズ， インコーポレイテッド レムデシビル治療方法
CN115996928A (zh) 2020-06-24 2023-04-21 吉利德科学公司 1’-氰基核苷类似物及其用途
AU2021296607B2 (en) 2020-06-25 2024-07-25 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV
FI4204421T3 (fi) 2020-08-27 2024-06-25 Gilead Sciences Inc Koostumuksia ja menetelmiä virusinfektioiden hoitoon
AU2022279234A1 (en) 2021-05-21 2023-12-07 Gilead Sciences, Inc. Pentacyclic derivatives as zika virus inhibitors
CN113880883A (zh) * 2021-11-11 2022-01-04 奥锐特药业股份有限公司 核苷类磷酸酯前药的制备方法
KR20240117588A (ko) 2021-12-03 2024-08-01 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염 치료용 화합물
MX2024006396A (es) 2021-12-03 2024-06-04 Gilead Sciences Inc Compuestos terapeuticos para la infeccion por el virus de inmunodeficiencia humana (vih).
WO2023167944A1 (fr) 2022-03-02 2023-09-07 Gilead Sciences, Inc. Composés et méthodes pour traiter des infections virales

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1135029A (en) * 1965-06-08 1968-11-27 Upjohn Co Improvements in or relating to cyclic phosphates and the manufacture thereof
US3929840A (en) * 1972-07-14 1975-12-30 Merck & Co Inc Labile esters of ({31 )(cis-1,2-epoxypropyl)phosphonic
US4816447A (en) * 1981-08-26 1989-03-28 Merck & Co., Inc. Anti-viral guanine compounds
US4816570A (en) * 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
CS263952B1 (en) * 1985-04-25 1989-05-12 Holy Antonin Remedy with antiviral effect
CS263951B1 (en) * 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
US4968788A (en) * 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
CS264222B1 (en) * 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
AU8092587A (en) * 1986-11-18 1988-05-19 Bristol-Myers Squibb Company Synthesis of purin-9-ylalkylenoxymethyl phosphonic acids
NZ222553A (en) * 1986-11-18 1991-07-26 Bristol Myers Co Phosphonomethoxyalkylene purine and pyrimidine derivatives and pharmaceutical compositions
AU610344B2 (en) * 1988-02-29 1991-05-16 Taiho Pharmaceutical Co., Ltd. 2'-deoxy-5-fluorouridine derivatives
EP0353955A3 (fr) * 1988-08-02 1991-08-14 Beecham Group Plc Composés chimiques
US5177064A (en) * 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
ATE194142T1 (de) * 1990-08-10 2000-07-15 Acad Of Science Czech Republic Verfahren zur herstellung von nukleotiden
GB9026164D0 (en) * 1990-12-01 1991-01-16 Beecham Group Plc Pharmaceuticals

Also Published As

Publication number Publication date
NL300131I1 (nl) 2003-10-01
HK1010053A1 (en) 1999-06-11
JP3164385B2 (ja) 2001-05-08
ATE167679T1 (de) 1998-07-15
US5792756A (en) 1998-08-11
EP0481214A1 (fr) 1992-04-22
DE69129650D1 (de) 1998-07-30
US5663159A (en) 1997-09-02
CA2051239C (fr) 2003-03-25
CA2051239A1 (fr) 1992-03-15
NL300131I2 (nl) 2004-02-02
EP0481214B1 (fr) 1998-06-24
DE10399025I2 (de) 2007-11-08
DE10399025I1 (de) 2003-10-23
BR1100467A (pt) 2000-06-06
DK0481214T3 (da) 1999-02-22
ES2118069T3 (es) 1998-09-16
JPH04230694A (ja) 1992-08-19
DE69129650T2 (de) 1999-03-25

Similar Documents

Publication Publication Date Title
LU91036I2 (fr) Adefovir dipivoxil et ses dérivés pharmaceutiquement acceptables (hepsera)
JP2900064B2 (ja) ヌクレオシド アナローグ類
CA2623522C (fr) 4'-nucleosides modifies comme agents antiviraux
US7018989B2 (en) Chemical compounds
JP3421335B2 (ja) 鏡像異性的に純粋なβ−Ｄ−（−）−ジオキソラン−ヌクレオシド
US7820631B2 (en) Anti-viral pyrimidine nucleoside analogues
US7019135B2 (en) Anti-viral pyrimidine nucleoside analogues
KR930006036A (ko) 퓨린 및 피리미딘의 불포화 비환식 포스포네이트 유도체
KR910006293A (ko) 항비루스성 화합물, 이의 제법 및 이를 함유하는 약학적 조성물
NZ223990A (en) Acylated 2',3'-dideoxynucleosides and pharmaceutical compositions
EP0205826A2 (fr) Phosphonylméthoxyalkyl-adénines pour le traitement de maladies à virus
JPH069680A (ja) ２’−フルオロ−２’，３’−ジデオキシピリミジンヌクレオシド
ES2187989T3 (es) Composicion de analogos de nucleotido y procedimiento de sintesis.
FR2374334A1 (fr) Nouveaux nucleosides utiles comme medicaments et procede pour leur preparation
RU96118248A (ru) 3'-замещенное производное нуклеозида
MY103801A (en) Dideoxydidehydrocarbocyclic nucleosides
De Clercq Antiviral activity of 5-substituted pyrimidine nucleoside analogues
KR880012628A (ko) 치료학적인 뉴클레오시드
JPH0680688A (ja) ４’−メチルヌクレオシド誘導体
EP0340778A3 (fr) Prodrogues de 2',3'-didéshydro-2',3'-didésoxynucléosides
KR930702374A (ko) 안티 센스 핵산 유도체
CA1303032C (fr) Nucleosides antiviraux
FR2444038A1 (fr) Derives de pyrazolo(1,5-c)quinazoline utiles comme medicaments et leurs procedes de preparation
EP0317728A3 (fr) Utilisation de dérivés de 9-(beta-D-arabinofuranosyl)adénine pour la préparation des compositions pharmaceutiques pour le traitement du SIDA